

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

## The impact of quality improvement initiatives to improve CKD referral patterns: A systematic review protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-055456
Article Type:	Protocol
Date Submitted by the Author:	13-Jul-2021
Complete List of Authors:	Ghimire, Anukul; University of Alberta Sultana, Naima; University of Alberta Ye, Feng; University of Alberta Hamonic, Laura; University of Alberta Grill, Allan; University of Toronto, Department of Family and Communit Medicine Singer , Alexander; University of Manitoba, Department of Family Medicine Akbari, Ayub; University of Ottawa, Department of Medicine Braam, Branko; University of Alberta Collister, David; University of Manitoba, Department of Medicine; McMaster University, Department of Medicine Jindal, Kailash; University of Alberta Courtney, Mark; University of Alberta Shah, Nikhil; University of Alberta Ronksley, Paul; University of Alberta Brimble, Kenneth Scott; McMaster University, Department of Medicine Shurraw, Sabin; University of Alberta Chou, Sophia; University of Calgary, Department of Medicine Shojai, Soroush ; University of Alberta Deved, Vinay; University of Alberta Wong, Andrew; Callingwood Medical Center Okpechi, Ikechi; University of Alberta Bello, A; University of Alberta
Keywords:	Chronic renal failure < NEPHROLOGY, Epidemiology < TROPICAL MEDICINE, PRIMARY CARE

## SCHOLARONE<sup>™</sup> Manuscripts

## A systematic review protocol

## Authors:

Anukul Ghimire<sup>1</sup> (anukul@ualberta.ca), Naima Sultana<sup>1</sup> (dr.naimasultana85@gmail.com), Feng Ye<sup>1</sup> (fye@ualberta.ca), Laura Hamonic<sup>1</sup> (lhamonic@ualberta.ca), Alan Grill<sup>2</sup> (AGrill@msh.on.ca), Alexander Singer<sup>3</sup> (alexandersinger@gmail.com), Ayub Akbari<sup>4</sup> (aakbari@toh.ca), Branko Braam<sup>1</sup> (bbraam@gmail.com), David Collister<sup>5,6</sup> (dtcollister@gmail.com), Kailash Jindal<sup>1</sup> (kjindal@ualberta.ca), Mark Courtney<sup>1</sup> (mc@ualberta.ca), Nikil Shah<sup>1</sup> (nshah1@ualberta.ca), Paul Ronksley<sup>7</sup> (peronksl@ucalgary.ca), Sabin Shurraw<sup>1</sup> (sshurraw@ualberta.ca), Scott Brimble<sup>6</sup> (brimbles@gmail.com), Scott Klarenbach<sup>1</sup> (swk@ualberta.ca), Sophia Chou<sup>7</sup> (Sophia.Chou@albertahealthservices.ca), Soroush Shojai<sup>1</sup> (shojai@ualberta.ca), Vinay Deved<sup>1</sup> (vdeved@telus.net), Andrew Wong<sup>8</sup> (andrewptwong@hotmail.com), Ikechi Okpechi<sup>1</sup>(iokpechi@ualberta.ca), Aminu K Bello<sup>1</sup> (aminu1@ualberta.ca)

## Author affiliations:

- 1: Faculty of Medicine and Dentistry, University of Alberta
- 2: Department of Family and Community Medicine, University of Toronto
- 3: Department of Family Medicine, University of Manitoba
- 4: Department of Medicine, University of Ottawa
- 5: Department of Medicine, University of Manitoba
- 6: Department of Medicine, McMaster University
- 7: Department of Medicine, University of Calgary
- 8: Callingwood Medical Center, Edmonton, Alberta

## **Corresponding author:**

Name: Aminu K. Bello

**Postal Address**: Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, T6G 2G3, Canada

Email: aminu1@ualberta.ca Phone: 780 492 5737

Abstract word count: 250

Manuscript word count: 2582

Key words: Chronic Renal Failure, Epidemiology, Primary Care

#### Abstract

### Introduction

Chronic kidney disease (CKD) is a global-health problem. A significant proportion of referrals to nephrologists for CKD management are early and guideline-discordant, which may lead to an excess number of referrals and increased wait-times. Various initiatives have been tested to increase the proportion of guideline-concordant referrals and decrease wait times. This paper describes the protocol for a systematic review to study the impacts of quality improvement initiatives aimed at decreasing the number of non-guideline concordant referrals, increasing the number of guideline-concordant referrals, and decreasing wait times for patients to access a nephrologist.

#### Methods and analysis

We developed this protocol by using the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols (PRISMA-P 2015). We will search empirical electronic databases (e.g. MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, PsycINFO) and grey literature for st1udies designed to improve guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD from primary care to nephrology. Our search will include all studies published from database inception to April 2021 with no language restrictions. The studies will be limited to referrals for adult patients to nephrologists. Referrals of CKD patients from non-nephrology specialists (e.g. general internal medicine) will be excluded.

### Ethics and dissemination

Ethics approval will not be required, as we will analyze data from studies that have already been published and are publicly accessible. We will share our findings using traditional approaches,

1 2	
2 3 4	including scientific presentations, open access peer-reviewed platforms, and appropriate
5 6	government and public health agencies.
7 8 9	PROSPERO registration
10 11	# CRD42021247756
12 13	
14 15	
16 17	
18 19	
20 21	
22	
23 24	
25 26	
27 28	
29 30	
31 32	
33 34	
35 36	
37 38	
39 40	
41 42	
43 44	
45 46	
47 48	
49 50	
51 52	
53 54	
55 56	
57 58	
58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## Article Summary

## Strengths and limitations of this study

- Our proposed study will focus on improving referral patterns to specialist kidney care which has the potential to increase the proportion of guideline-concordant referrals and decrease wait times for CKD patients.
- Our study findings can be used to form focus groups in the future that will incorporate opinions of patients, policy makers, and scientific researchers to make the objectives of improving CKD referral patterns more meaningful for all stakeholders.
- Our study may reveal which quality improvement (QI) initiatives best improve patient outcomes (e.g. wait times).
- Given that the definition of appropriate referral is usually not uniform across studies, our analysis will be based on different local guidelines, which might affect the interpretation of our results.
- As we anticipate that few articles will report on healthcare costs as part of QI initiatives, we may not be able to report on how changes in healthcare costs impact QI initiatives.

### Introduction

Chronic kidney disease (CKD) has become a serious global health concern. In 2017, CKD was reported as the cause of death for approximately 1.2 million people worldwide,<sup>1</sup> and estimates indicate that the number of patients with end-stage kidney disease (ESKD) requiring kidney replacement therapy (KRT) will continue to increase worldwide, reaching 5.4 million by 2030.<sup>2</sup>

Primary health care (PHC) practitioners play a significant role in managing earlier stages of CKD, when the focus is on addressing the risk factors for CKD progression, such as diabetes, hypertension, and other comorbidities.<sup>3,4</sup> Estimates from Alberta, Canada indicate that up to 95% of people with CKD are managed in the PHC setting.<sup>5</sup> Another study reported that 71.9 per 1,000 patients with advanced CKD (stages 3-5) in Canada are also managed in the PHC setting.<sup>6</sup> CKD management is costly to the healthcare system<sup>7–10</sup> and cost per person increases as CKD progresses.<sup>11,12</sup> Thus, effective CKD management at the PHC level has the potential to greatly reduce costs to the health care system, especially given the significantly high costs associated with KRT.<sup>12–14</sup>

Various guidelines and summary papers,<sup>3,4,15,16</sup> toolkits,<sup>17</sup> and referral pathways<sup>18</sup> are available to help PHC practitioners manage CKD and decide which patients should or should not be referred to nephrologists. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines include specific recommendations for referral to nephrology, including but not limited to eGFR values, urine protein abnormalities, and CKD progression.<sup>16</sup> Despite these internationally recognized recommendations, referral recommendations are not consistent, and vary between different health care systems.<sup>15,16,19</sup> For example, the Canadian Society of Nephrology recommends

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

referring CKD patients to nephrology when ACR exceeds 60 mg/mmol whereas KDIGO stipulates that referral should be initiated when ACR exceeds 30 mg/mmol.<sup>15</sup>

Timely referrals to nephrology have been shown to be linked to initiation of CKD-specific therapies and appropriate initiation of KRT.<sup>20,21</sup> Although it is well known that late referrals increase the risk of mortality, worsen post dialysis outcomes, and are associated with lengthy hospital stays and treatment costs,<sup>22–24</sup> not much is known about the implications of early—specifically, non-guideline concordant—referrals. Undoubtedly, non-guideline concordant referrals and prolonged wait times, and thereby delay access to specialty care<sup>25</sup> such as nephrology.

It has been shown that approximately 40% of referrals to nephrology for CKD management are unnecessary and not concordant with guidelines.<sup>26,27</sup> There may be various reasons for this. First, primary care physicians may not be comfortable with certain aspects of CKD management. For example, non-nephrology practices tend to adhere less often to monitoring parathyroid hormone, performing follow-up measurements of urine ACR, and various other aspects of CKD care.<sup>28,29</sup> Second, specialty guidelines are continuously being expanded and updated, which places a burden on primary care physicians who must become familiar with each one.<sup>28,30,31</sup> Overall, this is an area where quality improvement (QI) initiatives may add substantial value by improving provider confidence, patient care, and health efficiency

QI analysis is an evolving area in health care with the potential to greatly influence practice patterns and reduce quality gaps in various areas of health care. A quality gap is the difference

between health care outcomes and processes in the current state versus what can be achieved by applying professional expertise and implementing QI initiatives.<sup>32</sup> With regard to CKD referrals, outcome-level gaps include changes in wait times or the total number of referrals, and process-level gaps are reflected in how many primary care referrals are found to be guideline-concordant versus discordant.

QI initiatives are developed to reduce these gaps and inform interventions aimed at improving health outcomes by increasing the rate of effective practices in healthcare. Various taxonomies have been developed to classify QI initiatives into sub-groups based on target focus and delivery method.<sup>32–36</sup> In a previous systematic review, Faulkner et al. examined interventions in PHC focused on influencing referral rates from primary to secondary care in the United Kingdom.<sup>37</sup> The authors found that most interventions targeting referral rates are professional or organizational in nature, and that organizational interventions tend to reduce referrals to specialist care. Researchers also examined referrals from primary care to specialists in an updated Cochrane systematic review published in 2011, and found that educational activities and the use of structured referral sheets are the only interventions that impact referral rates.<sup>38</sup> These methods, however, have not demonstrated the same effectiveness with regard to referrals in the CKD population. A study from Ontario, Canada failed to show a significant change in the proportion of appropriate referrals from primary care after the implementation of a CKD toolkit and educational interventions for PHC providers.<sup>17</sup> Thus, further work is needed to identify which types of interventions have the potential to reduce overall and guideline-discordant referrals, improve wait times to specialist care, and close quality gaps in referral patterns from PHC providers for the CKD population.

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

The key objective for this review is to determine the impacts of various QI initiatives on processbased measures of CKD referral patterns from PHC to nephrology, including wait times, number of referrals, and/or proportion of guideline-concordant referrals. This is critically important, as PHC plays a prominent role in managing CKD<sup>6</sup> and our group has collected preliminary data indicating that a large proportion of referrals from PHC may be guideline-discordant, thereby potentially contributing to increased wait times.

#### Methods

#### Study design

We will conduct a systematic review of studies reporting on the impact of QI initiatives aimed at ensuring appropriate referral of patients with CKD from PHC to clinical nephrology programs. PHC providers are defined as family physicians, family doctors, and general practitioners (including nurse practitioners) in the primary care setting; we will exclude general internists and pediatricians who may be considered PHC providers in certain geographic regions.<sup>38</sup> The protocol for this study is based on Preferred Reporting Items for Systematic reviews and Meta-Analysis for Protocols 2015 (PRISMA-P-2015).<sup>39</sup> We will follow the PRISMA 2020 methodological guidelines (PRISMA 2020) as we conduct and report the findings of our systematic review.<sup>40</sup> The protocol for this study is registered with PROSPERO (CRD42021247756). We have outlined the types of studies to be included based on the nature of participants, interventions applied, outcomes reported, and study designs:

#### **BMJ** Open

Types of participants. We will include studies with participants over 18 years of age,
 regardless of sex, ethnicity, and geographic location who had been diagnosed with CKD
 but had not initiated KRT when a study intervention was first implemented.

- Types of interventions. We will include any initiative or program designed to ensure guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD from a primary care provider to a nephrology specialist. Various methods have been employed previously, including but not limited to: CKD management/referral pathways, toolkits, electronic referral systems, structured referral forms, and practice facilitation (i.e. consultant-led educational programs for primary care practitioners). We will categorize these studies based on the focus of the intervention, as described in previous studies: <sup>32,41</sup> (a) provider education; (b) provider reminder systems; (c) audit and feedback; (d) organizational change; (e) financial incentives, regulation, and policy; and (f) other. (Table 1).
- Types of studies. We will include randomized trials, controlled clinical trials, controlled before-after studies, interrupted time series studies, QI reports, and descriptive studies.

#### Search strategy

We have developed a search strategy in consultation with a research librarian. We will search several electronic databases—i.e. MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and PsycINFO—using a combination of controlled vocabulary search terms (i.e. Medical Subject Headings), and the MEDLINE search strategy (Supplementary Table S1). We also will manually search the references of publications meeting our criteria to identify any other work relevant to our review. Furthermore, we will search grey literature (conference abstracts

and proceedings, government and organizational reports, working papers, policy papers) in consultation with a librarian.

#### Study outcomes

Our outcomes of interest are changes to process-based QI measures: wait times, changes in the total number of referrals, and changes in the proportion of guideline-concordant referrals. We anticipate that included studies will have used various guidelines specific to geographic locations and local practice patterns. For studies that do not specify certain guideline referral criteria, we will document that referral criteria were not used.

## Data collection and analysis

The PRISMA flow diagram summarizes the recommended study selection process (Figure 1). To screen and select studies to be included, we will use a two-stage collaborative review process. In the first stage, two reviewers (AG and NS) will independently review titles and abstracts of retrieved studies based on the inclusion and exclusion criteria listed in Table 2. In the second stage, full texts of the selected studies will be obtained by these reviewers and analyzed independently to determine eligibility for inclusion in our final review. If necessary, a third reviewer (IO) may be involved to evaluate any discrepancies and advise in cases of disagreement. For any excluded study, we will record at least one reason for exclusion.

## Data extraction and management

Two reviewers will independently retrieve data and enter the summarized details into a data extraction form in Microsoft Excel. Data will include type of study, study design, publication year, first author, location of study and local healthcare system (e.g. private vs. public), CKD

stages included in study, assessment of kidney function (eGFR, serum creatinine, and urine albumin levels), referral guidelines/criteria used, a description of the QI intervention utilized, duration of intervention and follow up, wait times, and changes in total number of referrals and the proportion of guideline-concordant referrals.

#### Assessment of risk of bias in included studies

We will adapt and utilize the Cochrane Effective Practice and Organization of Care (EPOC) risk of bias criteria<sup>42</sup> to assess methodological quality and evaluate risk of bias in our retrieved studies. The risk of bias per study will be displayed in a risk of bias summary table, and any discrepancies will be resolved by a third reviewer.

#### Data synthesis and analysis

We will report changes in wait times, total referrals, and the proportion of guideline-concordant referrals associated with the QI interventions utilized in each study. Changes in the number of referrals, the proportion of guideline-concordant referrals, and other outcomes associated with QI interventions will be presented as absolute values and reported in the same way across all studies. All wait times will be reported as number of days.

If concerns arise regarding missing or unclear data in the studies analyzed, we will contact the authors to request information related to study methods, referral criteria used, and changes in guideline-concordant referrals. Missing outcome data will be summarized in the data extraction form and noted in the risk of bias section. Characteristics of included studies will be summarized in tables. Intervention effects will be calculated as relative risks (RRs) with 95% CIs for

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

dichotomous data, and mean differences (MDs) with 95% CIs for continuous variables. If we identify a sufficient number of studies, and clinical and methodological heterogeneity are reasonable, we will perform a meta-analysis to summarize pooled results using a random effects model.<sup>43</sup> Statistical heterogeneity will be quantified using  $I^2$  statistics<sup>44</sup> in each analysis. If heterogeneity between studies is high ( $I^2 > 50\%$ ), then data will be reported descriptively and we will provide a narrative synthesis of included studies using the Synthesis Without Meta-analysis (SWiM) reporting guideline as a framework.<sup>45</sup> We will assess publication bias using a regression-based test<sup>46</sup> and by visually inspecting funnel plots.

We will conduct a stratified meta-analysis by study characteristics. These include: the use of KDIGO guidelines vs. others, CKD stage at referral, and country income group (low and middle income vs. high income). We will perform categorical comparisons of the different types of QI interventions (i.e., provider education; provider reminder systems; audit and feedback; organizational change; financial incentives, regulation, and policy; and other).<sup>32</sup> We will compare the number of QI interventions in each category and the overall impacts of each on wait times, referral numbers, and the proportion of guideline-concordant referrals. This information will be summarized in table format, similar to previous studies that have examined the impacts of OI interventions on referral rates.<sup>37,38</sup>

#### Patient and public involvement

This protocol for a systematic review will not utilize patient or public involvement. Because no patient data will be collected at this step, this study does not require ethics approval. However, we hope to form focus groups in the future where we will promote patient engagement by

soliciting and incorporating the opinions of CKD patients regarding the relevance and implications of the study protocol and results. We hope to form similar focus groups with PHC providers. We also will involve policy makers at Alberta Health Services who will be interested in analyzing QI measures to enhance local health policies and practices. Furthermore, we will collaborate with scientific researchers at our institutions and others who are interested in this topic and have performed relevant work in this field. These groups will be engaged after the protocol is published and the results of the systematic review have been synthesized.

#### Timeline

We will collect data and develop our database from August to December 2021, analyze our data and compile our results from January to June 2022, and engage in knowledge translation activities from July to December 2022 (Figure 2).

#### Ethics and dissemination

Ethics approval will not be needed for our project since we will analyze data from already published studies. Our findings will be shared using traditional approaches, including open access peer-reviewed publication(s), presentations at meetings, and a report.

#### Discussion

QI initiatives have significant potential to close quality gaps, improve health systems, and enhance patient outcomes. To the best of our knowledge, no systematic reviews have been performed to examine different QI interventions that have been trialed to ensure appropriate referrals of CKD patients from PHC to nephrology. Our analysis will yield a summary of which types of QI interventions improve referral patterns. These results can guide the strategic

implementation of future QI initiatives to improve referral patterns and may ultimately enhance knowledge and CKD management practices in primary care settings, improve referral and triage systems, and increase the proportion of guideline-concordant referrals of CKD patients. These implications are significant, especially for public health care systems which may be burdened by both the costs of chronic disease management and long wait times for patients to access

specialist care.

#### Data statement

We will make data available upon reasonable request.

#### **Funding statement**

This work is supported by a Canadian Institutes of Health Research (CIHR) Project Scheme Grant and AMGEN Canada Incorporated Clinical Innovation Grant awarded to AB. The funders played no role in preparing the protocol content or in drafting the manuscript.

**Competing interest statement** 

None

## **Author contributions**

AG, NS, FY, IO, and AB developed the concept and drafted the manuscript. FY produced figures for manuscript. NS registered the study with PROSPERO. All authors were involved in

developing the protocol methods and revising the manuscript. All authors approved the final version to be published.

#### Acknowledgements

The authors thank Ms. Sophanny Tiv for her assistance in producing figures for the manuscript.

to beet eviewony

## References

- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709-733. doi:10.1016/S0140-6736(20)30045-3
- Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet*. 2015;385(9981):1975-1982. doi:10.1016/S0140-6736(14)61601-9
- Grill AK, Brimble S. Approach to the detection and management of chronic kidney disease: *Can Fam Physician*. 2018;64(10):728-735.
   http://www.ncbi.nlm.nih.gov/pubmed/30315015%0Ahttp://www.ncbi.nlm.nih.gov/pubme d/30315015
- Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. Practical approach to detection and management of chronic kidney disease for the primary care clinician. *Am J Med.* 2016;129(2):153-162.e7. doi:10.1016/j.amjmed.2015.08.025
- Alberta Health Services. Kidney Health Strategic Clinical Network 2016–2019 transformational roadmap. Published online 2019. http://www.albertahealthservices.ca/assets/about/scn/ahs-scn-kh-transformational-roadmap.pdf
- Bello AK, Ronksley PE, Tangri N, et al. Prevalence and demographics of CKD in Canadian primary care practices: a cross-sectional study. *Kidney Int Reports*. 2019;4(4):561-570. doi:10.1016/j.ekir.2019.01.005

1 2		
3 4	7.	Manns B, McKenzie SQ, Au F, Gignac PM, Geller LI. The financial impact of advanced
5 6		kidney disease on Canada Pension Plan and private disability insurance costs. Can J
7 8 9		Kidney Heal Dis. 2017;4(1):2054358117703986. doi:10.1177/2054358117703986
10 11	8.	Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic
12 13 14		kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc
15 16		Nephrol. 2004;15(5):1300-1306. doi:10.1097/01.ASN.0000125670.64996.BB
17 18 19	9.	Wyld MLR, Lee CMY, Zhuo X, et al. Cost to government and society of chronic kidney
20 21		disease stage 1-5: a national cohort study. Intern Med J. 2015;45(7):741-747.
22 23 24		doi:10.1111/imj.12797
25 26	10.	Manns B, Hemmelgarn B, Tonelli M, et al. The cost of care for people with chronic
27 28 29		kidney disease. Can J Kidney Heal Dis. 2019;4(6):2054358119835521.
30 31		doi:10.1177/2054358119835521
32 33	11	Hanavautt A.A. Sagal IE. Zhua V. Haaraar TI. Ingi K. Williams D. Madiaal aasta of
34 35	11.	Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of
36 37		CKD in the medicare population. J Am Soc Nephrol. 2013;24(9):1478-1483.
38 39		doi:10.1681/ASN.2012040392
40 41	12.	Golestaneh L, Alvarez PJ, Reaven NL, et al. All-cause costs increase exponentially with
42 43		increased chronic kidney disease stage. <i>Am J Manag Care</i> . 2017;23(10 Suppl):S163-S172.
44 45		
46 47	13.	Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in
48 49		Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ.
50 51 52		2007;7(2-3):149-169. doi:10.1007/s10754-007-9022-y
53 54 55	14.	Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage
56 57 58		16
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

	renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis.
	2002;40(3):611-622. doi:10.1053/ajkd.2002.34924
15.	Akbari A, Clase CM, Acott P, et al. Canadian Society of Nephrology commentary on the
	KDIGO clinical practice guideline for CKD evaluation and management. Am J Kidney
	Dis. 2015;65(2):177-205. doi:10.1053/j.ajkd.2014.10.013
16.	KDIGO, CKD. KDIGO CPG for evaluation & management of CKD 2013. Kidney Int
	Suppl. 2013;3(1):1-150.
17.	Brimble KS, Boll P, Grill AK, et al. Impact of the KidneyWise toolkit on chronic kidney
	disease referral practices in Ontario primary care: a prospective evaluation. BMJ Open.
	2020;10(2):e032838. doi:10.1136/bmjopen-2019-032838
18.	CKD pathway. Accessed June 12, 2021. http://www.ckdpathway.ca/
19.	De Coster C, McLaughlin K, Noseworthy TW. Criteria for referring patients with renal
	disease for nephrology consultation: a review of the literature. J Nephrol. 2010;23(4):399-
	407.
20.	Hommel K, Madsen M, Kamper AL. The importance of early referral for the treatment of
	chronic kidney disease: a Danish nationwide cohort study. BMC Nephrol. 2012;13:108.
	doi:10.1186/1471-2369-13-108
21.	Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services
	for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev.
	2014;6:CD007333. doi:10.1002/14651858.CD007333.pub2
22.	Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system
	17

1 ว		
2 3 4		characteristics associated with late referral in chronic kidney disease. BMC Nephrol.
5 6 7		2008;9:3. doi:10.1186/1471-2369-9-3
8 9	23.	Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk
10 11 12		among new ESRD patients in the United States. Am J Kidney Dis. 2003;41(2):301-318.
12 13 14		doi:10.1053/ajkd.2003.50038
15 16 17	24.	Kazmi WH, Obrador GT, Khan SS, Pereira BJG, Kausz AT. Late nephrology referral and
18 19		mortality among patients with end-stage renal disease: a propensity score analysis.
20 21 22		Nephrol Dial Transplant. 2004;19(7):1808-1814. doi:10.1093/ndt/gfg573
23 24	25.	MacKinnon JC. Wait times in Canada. Healthc Manag Forum. 2017;30(4):190-192.
25 26 27		doi:10.1177/0840470417700162
28 29 30	26.	Wright J, Glenister KM, Thwaites R, Terry D. The importance of adequate referrals for
31 32		chronic kidney disease. Aust J Gen Pract. 2018;47(1-2):58-62. doi:10.31128/AFP-08-17-
33 34		4302
35 36 37	27.	Lane C, Pirabhahar S, Robins J, Tranter S, Brown M, Katz I. Improving nephrology
38 39 40		service delivery—accessing the specialist. Aust Fam Physician. 2016;45(4):223-228.
41 42	28.	Bello AK, Ronksley PE, Tangri N, et al. Quality of chronic kidney disease management in
43 44		Canadian primary care. JAMA Netw open. 2019;2(9):e1910704.
45 46 47		doi:10.1001/jamanetworkopen.2019.10704
48 49 50	29.	Patwardhan MB, Samsa GP, Matchar DB, Haley WE. Advanced chronic kidney disease
50 51 52		practice patterns among nephrologists and non-nephrologists: a database analysis. Clin J
53 54		Am Soc Nephrol. 2007;2(2):277-283. doi:10.2215/CJN.02600706
55 56 57		
58 59		18
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

30.	Østbye T, Yarnall KSH, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time
	for management of patients with chronic diseases in primary care? Ann Fam Med.
	2005;3(3):209-214. doi:10.1370/afm.310
31.	Yarnall KSH, Pollak KI, Østbye T, Krause KM, Michener JL. Primary care: is there
	enough time for prevention? Am J Public Health. 2003;93(4):635-641.
	doi:10.2105/AJPH.93.4.635
32.	Shojania K, McDonald K, Watcher R, Owens D. Closing the quality gap: a critical
	analysis of quality improvement strategies. Volume 1: series overview and methodology.
	Technical Review 9; 2004.
33.	Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult
	immunization and cancer screening services: A meta-analysis. Ann Intern Med.
	2002;136(9):641-651. doi:10.7326/0003-4819-136-9-200205070-00006
34.	Stafford RS. Alternative strategies for controlling rising cesarean section rates. JAMA.
	1990;263(5):683-687. doi:10.1001/jama.1990.03440050077037
35.	Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease
	management programmes for patients with chronic illnesswhich ones work? Meta-
	analysis of published reports. BMJ. 2002;325:925. doi:10.1136/bmj.325.7370.925
36.	Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of
	systematic reviews of interventions. Med Care. 2001;39(8 Suppl 2):II2-45.
37.	Faulkner A, Mills N, Bainton D, et al. A systematic review of the effect of primary care-
	based service innovations on quality and patterns of referral to specialist secondary care.
	19

#### **BMJ** Open

1			
2 3 4		Br J Gen Pract. 2003;53:878-884.	
5 6		http://www.ingentaconnect.com/content/rcgp/bjgp/2003/00000053/00000496/art00011	1%5
7 8 9		Cnhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1314732/pdf/14702909.pdf	
10 11	38.	Akbari A, Mayhew A, Al-Alawi MA, et al. Interventions to improve outpatient referra	ıls
12 13 14		from primary care to secondary care. Cochrane Database Syst Rev. 2008;4:CD005471	•
15 16		doi:10.1002/14651858.CD005471.pub2	
17 18 19	39.	Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review	V
20 21		and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.	
22 23 24		doi:10.1186/2046-4053-4-1	
25 26 27	40.	Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic	с
28 29		reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:10.	3-
30 31		112. doi:10.1016/j.jclinepi.2021.02.003	
32 33 34	41.	McDonald KM, Chang C, Schultz EJ. Methods research report. Through the quality	
35 36		kaleidoscope: reflections on the science and practice of improving health care quality;	•
37 38 39		2013. Accessed June 13, 2021. www.EffectiveHealthCare.ahrq.gov/reports/final.cfm.	
40 41 42	42.	Cochrane Effective Practice and Organisation of Care (EPOC). Suggested risk of bias	
43 44		criteria for EPOC reviews. 2017;1-4.	
45 46		https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-	
47 48 49		authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf	
50 51 52	43.	DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.	
53 54		1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2	
55 56			
57 58			20

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool.

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

- 45. Campbell M, Mckenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. *BMJ*. 2020;368:16890. doi:10.1136/bmj.16890
- Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. 46. ol Assess. 2000, . Health Technol Assess. 2000;4(10). doi:10.3310/hta4100

Intervention type Provider education Provider reminder systems	Definition Interventions aimed at training care providers, including educa workshops/meetings, outreach programs, and distribution of educational materials Providing specific information about clinical encounters with t
Provider reminder systems	Providing specific information about clinical encounters with t
	of prompting clinicians to recall information or promote a cert aspect of care
Audit and feedback	Methods that provide a review of clinical performance for heaproviders and institutions to help improve quality of a certain care
Other	workshops meetings, outeach programs, and distribution of educational materials Providing specific information about clinical encounters with of prompting clinicians to recall information or promote a cer aspect of care Methods that provide a review of clinical performance for hea providers and institutions to help improve quality of a certain care Interventions not covered in the previously listed items, e.g. organizational change initiatives, financial incentives, patient systems, patient education, promotion of self-management, ar facilitated relay of clinical data to providers

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

	Inclusion criteria	Exclusion criteria
-	Studies involving CKD patients who	- Studies where referrals are not from
	are not being managed with KRT.	PHC to nephrology (e.g. referrals from
		or to general internal medicine for
-	Studies reporting changes in process-	CKD).
	based QI measures (wait times, number	
	of referrals, or changes in guideline-	- Review articles, editorials, letters to the
	concordant referrals) for CKD patients.	editor, commentaries, case studies, case
		reports, images.
-	Studies reporting at least one outcome	
	measure (referral numbers, rate or	- Studies where we cannot obtain
	proportion of guideline concordant	relevant data (e.g. method of
	referrals, or wait times).	intervention or outcomes reported) even
		after contacting authors.
-	No restrictions on publication date.	
		- Studies where the outcomes of interest
-	No restrictions on language.	(referral numbers, wait times,
		guideline-concordant referral rate) are
-	No restrictions on the referral	not clearly reported.
	guidelines (e.g. KDIGO vs.	
	local/national guidelines) used.	

<mark>Su</mark> j	oplementary Table S1
1	exp Renal Insufficiency, Chronic/
	Chronic Kidney disease*.mp.
	chronic kidney insufficienc*.mp.
	chronic renal disease*.mp.
	chronic renal insufficienc*.mp.
	CKD.mp.
	Renal fail*.mp.
	Kidney fail*.mp.
	or/1-8
	0. Organizational innovation/
	. clinical audit/ or medical audit/ or nursing audit/
	2. Quality Improvement/
	6. education/ or education, professional/ or education, continuing/ or education, medi
	ntinuing/ or education, nursing, continuing/ or education, professional, retraining/
	. (Quality* adj2 improv*).mp.
	6. ((Provider or doctor* or physician* or nurse* or health personnel* or healthcare
	ersonnel*) adj4 (educat* or learn* or "reminder system*")).mp.
	5. (Organization* adj3 (change* or restructure* or revamp or reform* or revise* or
	novat*)).mp.
	/. Audit*.mp.
18	B. Feedback/
19	P. <u>feedback.mp</u> .
20	). Physician Incentive Plans/
	. (financ* adj2 incentiv*).mp.
	2. (incent* adj2 (plan or plans)).mp.
	s. social control, formal/ or government regulation/ or mandatory programs/ or social
	ntrol policies/ or organizational policy/ or public policy/ or health policy/ or health c
-	form/
	. regulat*.mp.
	. (policy or policies).mp.
	5. or/10-25
	7. "Referral and Consultation"/ or (referral* or consultation* or consults or consult).n
	3. 26 and 27
	0. (((Improv* or amerilior* or better or enhance* or correct* or increase* or progress
	cilitat* or promote* or raise* or augment* or elevate* or appropriate) adj3 (referral*
	nsultation* or consult or consults)) and (guide* or policy or policies or regulation* or alloit* or non ort*)) and
	olkit* or report*)).mp.
	0. ((Reduce or reduction* or decrese* or lessen* or minimize* or diminish* or lower*
	roid*) adj3 ((unnecessary or avoidable or superfluous or unneeded or irrelevant or lat aditional) adj2 (referral* or consultation* or consult or consults))).mp.

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool.

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

1 2
3 4
- 5 6
6 7 8
8 9
8 9 10 11
12
13 14
15 16
16 17
10
19 20
21
22 23
24 25
26 27
28
29 30
31 32
33
34 35
36 37
38
39 40
41 42
43
44 45
46 47
48
49 50
51
52


59


60

31. wait\* time\*.mp. and ((referral\* or consultation\* or consult or consults).mp. or
"Referral and Consultation"/) and (guide\* or policy or policies or regulation\* or toolkit\* or reporting).mp.
32. 28 or 29 or 30 or 31
33. 9 and 32

**BMJ** Open

tor peer terien only





	2021			2022		
Jan	<ul> <li>Feb Mar Apr May Jun Jul Aug</li> <li>Jan 2021 - Jul 2021</li> <li>Protocol development</li> <li>Identification of relevant QI frameworks</li> <li>Selection of studies</li> <li>Data extraction tool development/relevance form</li> <li>Prospero registration</li> <li>Publication of protocol</li> </ul>	Sep Oct Nov Dec Jan Aug 2021 - Dec 2021 Identification of relevant publications Data extraction Database development Risk of bias assessment Analysis	Feb Mar Apr May Jun Jan 2022 - Jun 2022 • Manuscript writing/ reporting of results • Publication of original manuscript • Presentation at scientific meetings	Jul	Aug Sep Oct Nov Dec Jul 2022 - Dec 2022 KT activities and tools development (lay summaries and policy briefs) Engagement with relevant policy makers, primary care and referral coordinators to effect practice and/or policy change Develop recommendations for guideline developers	Jan

AT-LZS. Downloaded from http://bmjopen.2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright,אופנווקוספראליפנולאלאלאלאפנולאלאלאלאפנולאלאלאלאפראלים איפואלאלאלאלאלאלאלאלאלאלאלאלאלאלאלא

# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

# Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page a
		Reporting Item	Number
Title			
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	1
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic	N/A
		review, identify as such	
	For nee	r review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3	Registration			
4 5		<u>#2</u>	If registered, provide the name of the registry (such as	2
6 7			PROSPERO) and registration number	
8 9 10 11	Authors			
12 13 14	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all	1
15 16			protocol authors; provide physical mailing address of	
17 18			corresponding author	
19 20	Contribution	#3b	Describe contributions of protocol authors and identify the	14
21 22 23	Contribution	<u>#30</u>	guarantor of the review	14
23 24 25			guarantor of the review	
26 27	Amendments			
28 29		<u>#4</u>	If the protocol represents an amendment of a previously	N/A
30 31			completed or published protocol, identify as such and list	
32 33 34			changes; otherwise, state plan for documenting important	
35 36			protocol amendments	
37 38			O,	
39 40	Support			
41 42 43	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	14
44 45 46 47	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	14
48 49	Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or	14
50 51	funder		institution(s), if any, in developing the protocol	
52 53 54 55 56 57	Introduction			
58 59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is	3-8	BMJ
3 4 5			already known		Open:
6 7	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review	8	first pul
8 9 10			will address with reference to participants, interventions,	т	blished
11 12			comparators, and outcomes (PICO)	rotecte	1 as 10.
13 14 15	Methods			Protected by copyright, including for uses 23 9, 9 8-9	BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022
16 17 18	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study	yright, 8-9, 23 <b>t</b> ,	jopen-2
19 20			design, setting, time frame) and report characteristics (such	includ	021-05
21 22 23			as years considered, language, publication status) to be	ing for	5456 o
23 24 25			used as criteria for eligibility for the review	uses r	n 21 A
26 27	Information	#9	Describe all intended information sources (such as	elated 8-9	pril 20
28 29		<u>#3</u>	electronic databases, contact with study authors, trial	to tex	22. Do
30 31 32	sources		registers or other grey literature sources) with planned dates	t and c	wnloa
33 34				data m	ded fro
35 36			of coverage	nining, Al	om htt
37 38	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one		o://bmj
39 40			electronic database, including planned limits, such that it	ning, a	open.l
41 42 43			could be repeated	nd simi	omj.cor
44 45 46	Study records -	<u>#11a</u>	Describe the mechanism(s) that will be used to manage	10 tech	n/ on M
47 48	data management		records and data throughout the review	training, and similar technologies	ay 5, 20
49 50 51	Study records -	<u>#11b</u>	State the process that will be used for selecting studies	<b>ب</b> ة 10	ded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA
52 53	selection process		(such as two independent reviewers) through each phase of		€partm
54 55			the review (that is, screening, eligibility and inclusion in		ent GE
56 57 58			meta-analysis)		:Z-LTA
59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

1 2	Study records -	<u>#11c</u>	Describe planned method of extracting data from reports	10
3 4	data collection		(such as piloting forms, done independently, in duplicate),	
5 6 7	process		any processes for obtaining and confirming data from	
, 8 9			investigators	
10 11 12	Data items	<u>#12</u>	List and define all variables for which data will be sought	9
12 13 14			(such as PICO items, funding sources), any pre-planned	
15 16 17			data assumptions and simplifications	
18 19	Outcomes and	<u>#13</u>	List and define all outcomes for which data will be sought,	10
20 21 22	prioritization		including prioritization of main and additional outcomes, with	
23 24 25			rationale	
26 27	Risk of bias in	<u>#14</u>	Describe anticipated methods for assessing risk of bias of	11
28 29	individual studies		individual studies, including whether this will be done at the	
30 31 32			outcome or study level, or both; state how this information	
33 34 35			will be used in data synthesis	
36 37	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be	11
38 39			quantitatively synthesised	
40 41 42	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe	11
43 44 45			planned summary measures, methods of handling data and	
45 46 47			methods of combining data from studies, including any	
48 49 50			planned exploration of consistency (such as I2, Kendall's $\tau$ )	
51 52	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as	11
53 54 55			sensitivity or subgroup analyses, meta-regression)	
56 57				
58 59		For neer	review only - http://bmiopen.hmi.com/site/about/quidelines.yhtml	

1 2	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the type	N/A
3			of summary planned	
4 5				
6 7	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as	11
8 9				
10			publication bias across studies, selective reporting within	Pr
11 12			studies)	otect
13 14				ed b
15	Confidence in	<u>#17</u>	Describe how the strength of the body of evidence will be	N/A cop
16 17	cumulative		assessed (such as GRADE)	Protected by copyright, including for uses related to text and data mining, Al
18 19	evidence			ht, in
20	evidence			clud
21 22	The PRISMA-P ela	boration	and explanation paper is distributed under the terms of the Creative	ing fo
23 24				or us
25	Commons Attribution	on Licens	se CC-BY. This checklist was completed on 28. June 2021 using	ës re
26 27	https://www.goodre	eports.org	g/, a tool made by the EQUATOR Network in collaboration with	latec
28 29	Penelope.ai			tot
30				ext a
31 32				nd da
33 34				ata m
35				nining
36 37				
38 39				training, and similar technologies.
40				ing, a
41 42				and s
43 44				imila
45				ır tec
46 47				hnol
48 49				ogie:
50				Ŀ,
51 52				
53 54				
55				
56 57				
58				
59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

## The impact of quality improvement initiatives to improve CKD referral patterns: A systematic review protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-055456.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Feb-2022
Complete List of Authors:	Ghimire, Anukul; University of Alberta Sultana, Naima; University of Alberta Ye, Feng; University of Alberta Hamonic, Laura; University of Alberta Grill, Allan; University of Toronto, Department of Family and Community Medicine Singer , Alexander; University of Manitoba, Department of Family Medicine Akbari, Ayub; University of Ottawa, Department of Medicine Braam, Branko; University of Alberta Collister, David; University of Manitoba, Department of Medicine; McMaster University, Department of Medicine Jindal, Kailash; University of Alberta Courtney, Mark; University of Alberta Shah, Nikhil; University of Alberta Ronksley, Paul; University of Calgary, Department of Medicine Shurraw, Sabin; University of Alberta Brimble, Kenneth Scott; McMaster University, Department of Medicine Klarenbach, Scott; University of Alberta Deved, Vinay; University of Alberta Deved, Vinay; University of Alberta Wong, Andrew; Callingwood Medical Center Okpechi, Ikechi; University of Alberta Bello, A; University of Alberta
<b>Primary Subject Heading</b> :	Renal medicine
Secondary Subject Heading:	Epidemiology, Renal medicine, Health services research
Keywords:	Chronic renal failure < NEPHROLOGY, Epidemiology < TROPICAL MEDICINE, PRIMARY CARE
	1



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## The impact of quality improvement initiatives to improve CKD referral patterns:

## A systematic review protocol

## Authors:

Anukul Ghimire<sup>1</sup> (anukul@ualberta.ca), Naima Sultana<sup>1</sup> (dr.naimasultana85@gmail.com), Feng Ye<sup>1</sup> (fye@ualberta.ca), Laura Hamonic<sup>1</sup> (lhamonic@ualberta.ca), Alan Grill<sup>2</sup> (AGrill@msh.on.ca), Alexander Singer<sup>3</sup> (alexandersinger@gmail.com), Ayub Akbari<sup>4</sup> (aakbari@toh.ca), Branko Braam<sup>1</sup> (bbraam@gmail.com), David Collister<sup>5,6</sup> (dtcollister@gmail.com), Kailash Jindal<sup>1</sup> (kjindal@ualberta.ca), Mark Courtney<sup>1</sup> (mc@ualberta.ca), Nikil Shah<sup>1</sup> (nshah1@ualberta.ca), Paul Ronksley<sup>7</sup> (peronksl@ucalgary.ca), Sabin Shurraw<sup>1</sup> (sshurraw@ualberta.ca), Scott Brimble<sup>6</sup> (brimbles@gmail.com), Scott Klarenbach<sup>1</sup> (swk@ualberta.ca), Sophia Chou<sup>7</sup> (Sophia.Chou@albertahealthservices.ca), Soroush Shojai<sup>1</sup> (shojai@ualberta.ca), Vinay Deved<sup>1</sup> (vdeved@telus.net), Andrew Wong<sup>8</sup> (andrewptwong@hotmail.com), Ikechi Okpechi<sup>1</sup>(iokpechi@ualberta.ca), Aminu K Bello<sup>1</sup> (aminu1@ualberta.ca)

## Author affiliations:

- 1: Faculty of Medicine and Dentistry, University of Alberta
- 2: Department of Family and Community Medicine, University of Toronto
- 3: Department of Family Medicine, University of Manitoba
- 4: Department of Medicine, University of Ottawa
- 5: Department of Medicine, University of Manitoba
- 6: Department of Medicine, McMaster University
- 7: Department of Medicine, University of Calgary
- 8: Callingwood Medical Center, Edmonton, Alberta

## **Corresponding author:**

Name: Aminu K. Bello

**Postal Address**: Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, T6G 2G3, Canada

Email: aminu1@ualberta.ca Phone: 780 492 5737

Abstract word count: 250

Manuscript word count: 2825

Key words: Chronic Renal Failure, Epidemiology, Primary Care

## Abstract

#### Introduction

Chronic kidney disease (CKD) is a global-health problem. A significant proportion of referrals to nephrologists for CKD management are early and guideline-discordant, which may lead to an excess number of referrals and increased wait-times. Various initiatives have been tested to increase the proportion of guideline-concordant referrals and decrease wait times. This paper describes the protocol for a systematic review to study the impacts of quality improvement initiatives aimed at decreasing the number of non-guideline concordant referrals, increasing the number of guideline-concordant referrals, and decreasing wait times for patients to access a nephrologist.

## Methods and analysis

We developed this protocol by using the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols (PRISMA-P 2015). We will search the following empirical electronic databases: MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, PsycINFO and grey literature for studies designed to improve guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD from primary care to nephrology. Our search will include all studies published from database inception to April 2021 with no language restrictions. The studies will be limited to referrals for adult patients to nephrologists. Referrals of CKD patients from non-nephrology specialists (e.g., general internal medicine) will be excluded.

## Ethics and dissemination

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool.

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Ethics approval will not be required, as we will analyze data from studies that have already been published and are publicly accessible. We will share our findings using traditional approaches, including scientific presentations, open access peer-reviewed platforms, and appropriate government and public health agencies.

PROSPERO registration # CRD42021247756

## Article Summary

## Strengths and limitations of this study

- Our proposed study will focus on improving referral patterns to specialist kidney care which has the potential to increase the proportion of guideline-concordant referrals and decrease wait times for CKD patients.
- Our study findings can inform focus groups in the future that will incorporate opinions of patients, policy makers, and scientific researchers to further explore methods in enhancing referral patterns from primary care to nephrologists.
- Our study may reveal which quality improvement (QI) initiatives best improve patient outcomes (e.g., wait times).
- Given that the definition of appropriate referral is usually not uniform across studies, our analysis will be based on different local guidelines, which might affect the interpretation of our results.

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### Introduction

Chronic kidney disease (CKD) has become a serious global health concern. In 2017, CKD was reported as the cause of death for approximately 1.2 million people worldwide,<sup>1</sup> and estimates indicate that the number of patients with end-stage kidney disease (ESKD) requiring kidney replacement therapy (KRT) will continue to increase worldwide, reaching 5.4 million by 2030.<sup>2</sup>

Primary health care (PHC) practitioners play a significant role in managing earlier stages of CKD, when the focus is on addressing the risk factors for CKD progression, such as diabetes, hypertension, and other comorbidities.<sup>3,4</sup> Estimates from Alberta, Canada indicate that up to 95% of people with CKD are managed in the PHC setting.<sup>5</sup> Another study reported that 71.9 per 1,000 patients with advanced CKD (stages 3-5) in Canada are also managed in the PHC setting.<sup>6</sup> CKD management is costly to the healthcare system<sup>7–10</sup> and cost per person increases as CKD progresses.<sup>11,12</sup> Thus, effective CKD management at the PHC level has the potential to greatly reduce costs to the health care system, especially given the significantly high costs associated with KRT.<sup>12–14</sup>

Various guidelines and summary papers,<sup>3,4,15,16</sup> toolkits,<sup>17</sup> and referral pathways<sup>18</sup> are available to help PHC practitioners manage CKD and decide which patients should or should not be referred to nephrologists. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines include specific recommendations for referral to nephrology, including but not limited to eGFR values, urine protein abnormalities, and CKD progression.<sup>16</sup> Despite these internationally recognized recommendations, referral recommendations are not consistent, and vary between different health care systems.<sup>15,16,19</sup> For example, the Canadian Society of Nephrology recommends

#### **BMJ** Open

referring CKD patients to nephrology when ACR exceeds 60 mg/mmol whereas KDIGO stipulates that referral should be initiated when ACR exceeds 30 mg/mmol.<sup>15</sup>

Timely referrals to nephrology have been shown to be linked to initiation of CKD-specific therapies and appropriate initiation of KRT.<sup>20,21</sup> Although it is well known that late referrals increase the risk of mortality, worsen post dialysis outcomes, and are associated with lengthy hospital stays and treatment costs,<sup>22–24</sup> not much is known about the implications of early— specifically, non-guideline concordant—referrals. Non-guideline concordant referrals may strain the health care system due to an increase in the number of overall referrals and prolonged wait times, and thereby delay access to specialty care<sup>25</sup> such as nephrology.

It has been shown that approximately 40% of referrals to nephrology for CKD management are not concordant with guidelines.<sup>26,27</sup> There may be various reasons for this. First, primary care physicians may not be comfortable with certain aspects of CKD management. For example, non-nephrology practices tend to adhere less often to monitoring parathyroid hormone, performing follow-up measurements of urine ACR, and various other aspects of CKD care.<sup>28,29</sup> Second, specialty guidelines are continuously being expanded and updated, which places a burden on primary care physicians who must become familiar with each one.<sup>28,30,31</sup> Overall, this is an area where quality improvement (QI) initiatives may add substantial value by improving provider confidence, patient care, and health efficiency

QI is an evolving area in health care with the potential to greatly influence practice patterns and reduce quality gaps in various areas of health care. A quality gap is the difference between health

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool .

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

care outcomes and processes in the current state versus what can be achieved by applying professional expertise and implementing QI initiatives.<sup>32</sup> With regard to CKD referrals, outcomelevel gaps include changes in wait times or the total number of referrals, and process-level gaps are reflected in how many primary care referrals are found to be guideline-concordant versus discordant.

OI initiatives are developed to reduce these gaps and inform interventions aimed at improving health outcomes by increasing the rate of effective practices in healthcare. Various taxonomies have been developed to classify QI initiatives into sub-groups based on target focus and delivery method.<sup>32–36</sup> In a previous systematic review, Faulkner et al. examined interventions in PHC focused on influencing referral rates from primary to secondary care in the United Kingdom.<sup>37</sup> The authors found that most interventions targeting referral rates are professional (defined as interventions such education for PHC, information provision, or guidelines) or organizational (defined as primary healthcare and specialist provider schemes, general practitioner fundholding schemes, and open access referral schemes) in nature, and that organizational interventions tend to reduce referrals to specialist care. Researchers also examined referrals from primary care to specialists in an updated Cochrane systematic review published in 2011, and found that educational activities and the use of structured referral sheets are the only interventions that impact referral rates.<sup>38</sup> These methods, however, have not demonstrated the same effectiveness with regard to referrals in the CKD population. A study from Ontario, Canada failed to show a significant change in the proportion of appropriate referrals from primary care after the implementation of a CKD toolkit and educational interventions for PHC providers.<sup>17</sup> Thus, further work is needed to identify which types of interventions have the potential to reduce

#### **BMJ** Open

overall and guideline-discordant referrals, improve wait times to specialist care, and close quality gaps in referral patterns from PHC providers for the CKD population.

The key objective for this review is to determine the impacts of various QI initiatives on processbased measures of CKD referral patterns from PHC to nephrology, including wait times, number of referrals, and/or proportion of guideline-concordant referrals. This is critically important, as PHC plays a prominent role in managing CKD<sup>6</sup> and our group has collected preliminary data indicating that a large proportion of referrals from PHC may be guideline-discordant, thereby potentially contributing to increased wait times.

#### Methods

#### Study design

We will conduct a systematic review of studies reporting on the impact of QI initiatives aimed at ensuring appropriate referral of patients with CKD from PHC to clinical nephrology programs. PHC providers are defined as family physicians, family doctors, and general practitioners (including nurse practitioners) in the primary care setting; we will exclude general internists and pediatricians who may be considered PHC providers in certain geographic regions.<sup>38</sup> We will also exclude studies that include general internists and/or pediatricians among eligible referral sources. We chose to exclude such studies given that our focus is to assess the impact of implementing QI on referrals from primary care to nephrology. Including studies with referrals from general internal medicine (GIM) and pediatrics could create heterogeneity among the studies and confound our outcome and conclusions given that GIM and pediatrics, in many places, are considered specialists rather than primary care. It is reassuring that this category of

referrals from general medicine and pediatrics are small (<10% of all referrals to nephrology) based on empirical information available to use, and the referral model within the Canadian health system where primary care providers (family physicians and GPs) constitute the main gatekeepers to specialist care. The protocol for this study is based on Preferred Reporting Items for Systematic reviews and Meta-Analysis for Protocols 2015 (PRISMA-P-2015).<sup>39</sup> We will follow the PRISMA 2020 methodological guidelines (PRISMA 2020) as we conduct and report the findings of our systematic review.<sup>40</sup> The protocol for this study is registered with PROSPERO (CRD42021247756). We have outlined the types of studies to be included based on the nature of participants, interventions applied, outcomes reported, and study designs:

- Types of participants. We will include studies with participants over 18 years of age,
   regardless of sex, ethnicity, and geographic location who had been diagnosed with CKD
   but had not initiated KRT when a study intervention was first implemented.
- Types of interventions. We will include any initiative or program designed to ensure guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD from a primary care provider to a nephrology specialist. Various methods have been employed previously, including but not limited to: CKD management/referral pathways, toolkits, electronic referral systems, structured referral forms, and practice facilitation (i.e., consultant-led educational programs for primary care practitioners). We will categorize these studies based on the focus of the intervention, as described in previous studies: <sup>32,41</sup> (a) provider education; (b) provider reminder systems; (c) audit and feedback; (d) organizational change; (e) financial incentives, regulation, and policy; and (f) other. (Table 1).

#### **BMJ** Open

Types of studies. We will include randomized trials, controlled clinical trials, controlled before-after studies, interrupted time series studies, QI reports, and descriptive studies.

#### Search strategy

We have developed a search strategy in consultation with a research librarian (LH) (Appendix 1). We will search the following electronic databases— MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and PsycINFO —using a combination of controlled vocabulary search terms; the MEDLINE search strategy is shown in Supplementary Table S1. We also will manually search the references of publications meeting our criteria to identify any other work relevant to our review. Furthermore, we will search grey literature (conference abstracts and proceedings, government and organizational reports, working papers, policy papers) in consultation with a librarian. CLIP

#### Study outcomes

Our outcomes of interest are changes to process-based QI measures: wait times, changes in the total number of referrals, and changes in the proportion of guideline-concordant referrals. We anticipate that included studies will have used various guidelines specific to geographic locations and local practice patterns. For studies that do not specify certain guideline referral criteria, we will document that referral criteria were not used.

#### Data collection and analysis

The PRISMA flow diagram summarizes the recommended study selection process (Figure 1). To screen and select studies to be included, we will use a two-stage collaborative review process. In the first stage, two reviewers (AG and NS) will independently review titles and abstracts of

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

retrieved studies based on the inclusion and exclusion criteria listed in Table 2. In the second stage, full texts of the selected studies will be obtained by these reviewers and analyzed independently to determine eligibility for inclusion in our final review. For both the first and second stages of screening, studies will be included if there is consensus between the two reviewers. If there is a disagreement, a third reviewer (IO) will resolve such conflicts and make decision on eligibility. For any excluded study, we will record at least one reason for exclusion.

#### Data extraction and management

Two reviewers will independently retrieve data and enter the summarized details into a data extraction form in Microsoft Excel. Data will include type of study, study design, publication year, first author, location of study and local healthcare system (e.g. private vs. public), CKD stages included in study, assessment of kidney function (eGFR, serum creatinine, and urine albumin levels), referral guidelines/criteria used, a description of the QI intervention utilized, duration of intervention and follow up, wait times, and changes in total number of referrals and the proportion of guideline-concordant referrals.

#### Assessment of risk of bias in included studies

We will adapt and utilize the Cochrane Effective Practice and Organization of Care (EPOC) risk of bias criteria<sup>42</sup> to assess methodological quality and evaluate risk of bias in our retrieved studies. The risk of bias per study will be displayed in a risk of bias summary table, and any discrepancies will be resolved by a third reviewer.

#### Data synthesis and analysis

Page 13 of 38

#### **BMJ** Open

We will report changes in wait times, total referrals, and the proportion of guideline-concordant referrals associated with the QI interventions utilized in each study. Changes in the number of referrals, the proportion of guideline-concordant referrals, and other outcomes associated with QI interventions will be presented as absolute values and reported in the same way across all studies. All wait times will be reported as number of days.

If concerns arise regarding missing or unclear data in the studies analyzed, we will contact the authors to request information related to study methods, referral criteria used, and changes in guideline-concordant referrals. Missing outcome data will be summarized in the data extraction form and noted in the risk of bias section. Characteristics of included studies will be summarized in tables. Intervention effects will be calculated as relative risks (RRs) with 95% CIs for dichotomous data, and mean differences (MDs) with 95% CIs for continuous variables. If we identify a sufficient number of studies, and clinical and methodological heterogeneity are reasonable, we will perform a meta-analysis to summarize pooled results using a random effects model.<sup>43</sup> Statistical heterogeneity will be quantified using *I*<sup>2</sup> statistics<sup>44</sup> in each analysis. If heterogeneity between studies is high ( $I^2 > 50\%$ ), then data will be reported descriptively and we will provide a narrative synthesis of included studies using the Synthesis Without Meta-analysis (SWiM) reporting guideline as a framework.<sup>45</sup> We will assess publication bias using a regression-based test<sup>46</sup> and by visually inspecting funnel plots.

We will conduct a stratified meta-analysis by study characteristics. These include: the use of KDIGO guidelines vs. others, CKD stage at referral, and country income group (low and middle income vs. high income). We will perform categorical comparisons of the different types of QI

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

interventions (i.e., provider education; provider reminder systems; audit and feedback; organizational change; financial incentives, regulation, and policy; and other).<sup>32</sup> We will compare the number of QI interventions in each category and the overall impacts of each on wait times, referral numbers, and the proportion of guideline-concordant referrals. This information will be summarized in table format, similar to previous studies that have examined the impacts of QI interventions on referral rates.<sup>37,38</sup>

#### Patient and public involvement

This protocol for a systematic review will not utilize patient or public involvement. Because no patient data will be collected at this step, this study does not require ethics approval. However, we hope to form focus groups in the future where we will promote patient engagement by soliciting and incorporating the opinions of CKD patients regarding the relevance and implications of the study protocol and results. We hope to form similar focus groups with PHC providers. We also will involve policy makers at Alberta Health Services who will be interested in analyzing QI measures to enhance local health policies and practices. Furthermore, we will collaborate with scientific researchers at our institutions and others who are interested in this topic and have performed relevant work in this field. These groups will be engaged after the protocol is published and the results of the systematic review have been synthesized.

#### Timeline

We will collect data and develop our database from August to December 2021, analyze our data and compile our results from January to June 2022, and engage in knowledge translation activities from July to December 2022 (Figure 2).

#### **BMJ** Open

Ethics approval will not be needed for our project since we will analyze data from already published studies. Our findings will be shared using traditional approaches, including open access peer-reviewed publication(s), presentations at meetings, and a report.

## Discussion

QI initiatives have significant potential to close quality gaps, improve health systems, and enhance patient outcomes. To the best of our knowledge, no systematic reviews have been performed to examine different QI interventions that have been trialed to ensure appropriate referrals of CKD patients from PHC to nephrology. Our analysis will yield a summary of which types of QI interventions improve referral patterns. These results can guide the strategic implementation of future QI initiatives to improve referral patterns and may ultimately enhance knowledge and CKD management practices in primary care settings, improve referral and triage systems, and increase the proportion of guideline-concordant referrals of CKD patients. These implications are significant, especially for public health care systems which may be burdened by both the costs of chronic disease management and long wait times for patients to access specialist care.

## Data statement

We will make data available upon reasonable request.

#### **Funding statement**

This work is supported by a Canadian Institutes of Health Research (CIHR) Project Scheme Grant (grant number: RES0046966) and AMGEN Canada Incorporated Clinical Innovation Grant (grant number: RES0041633) awarded to AB. The funders played no role in preparing the protocol content or in drafting the manuscript.

**Competing interest statement** 

None

#### **Author contributions**

AG, NS, FY, IO, and AB developed the concept and drafted the manuscript. FY produced figures for manuscript. LH drafted the search strategy. NS registered the study with PROSPERO. LH, AGrill, AS, AA, BB, DC, KJ, MC, NS, PR, SS, SB, SK, SC, SShojai, VD, and AW were involved in developing the protocol methods and revising the manuscript. All authors approved the final version to be published.

#### Acknowledgements

The authors thank Ms. Sophanny Tiv for her assistance in producing figures for the manuscript.

#### **Figures**

Figure 1: Study selection process

Figure 2: Project timeline

References
. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic
analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733.
doi:10.1016/S0140-6736(20)30045-3
Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney
disease: a systematic review. Lancet. 2015;385(9981):1975-1982. doi:10.1016/S0140-
6736(14)61601-9
Grill AK, Brimble S. Approach to the detection and management of chronic kidney
disease: Can Fam Physician. 2018;64(10):728-735.
http://www.ncbi.nlm.nih.gov/pubmed/30315015%0Ahttp://www.ncbi.nlm.nih.gov/pubme
d/30315015
. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. Practical approach to
detection and management of chronic kidney disease for the primary care clinician. Am J
Med. 2016;129(2):153-162.e7. doi:10.1016/j.amjmed.2015.08.025
Alberta Health Services. Kidney Health Strategic Clinical Network 2016–2019
transformational roadmap. Published online 2019.
http://www.albertahealthservices.ca/assets/about/scn/ahs-scn-kh-transformational-road-
map.pdf
Bello AK, Ronksley PE, Tangri N, et al. Prevalence and demographics of CKD in
Canadian primary care practices: a cross-sectional study. Kidney Int Reports.
2019;4(4):561-570. doi:10.1016/j.ekir.2019.01.005
15

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

7.	Manns B, McKenzie SQ, Au F, Gignac PM, Geller LI. The financial impact of advanced
	kidney disease on Canada Pension Plan and private disability insurance costs. Can J
	Kidney Heal Dis. 2017;4(1):2054358117703986. doi:10.1177/2054358117703986
8.	Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic
	kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc
	Nephrol. 2004;15(5):1300-1306. doi:10.1097/01.ASN.0000125670.64996.BB
0	Wuld MLD, Los CMV, Zhuo V, at al. Cost to government and society of abronic hidrory
9.	Wyld MLR, Lee CMY, Zhuo X, et al. Cost to government and society of chronic kidney
	disease stage 1–5: a national cohort study. <i>Intern Med J.</i> 2015;45(7):741-747.
	doi:10.1111/imj.12797
10.	Manns B, Hemmelgarn B, Tonelli M, et al. The cost of care for people with chronic
	kidney disease. Can J Kidney Heal Dis. 2019;4(6):2054358119835521.
	doi:10.1177/2054358119835521
11.	Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of
	CKD in the medicare population. J Am Soc Nephrol. 2013;24(9):1478-1483.
	doi:10.1681/ASN.2012040392
12.	Golestaneh L, Alvarez PJ, Reaven NL, et al. All-cause costs increase exponentially with
	increased chronic kidney disease stage. Am J Manag Care. 2017;23(10 Suppl):S163-S172.
10	
13.	Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in
	Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ.
	2007;7(2-3):149-169. doi:10.1007/s10754-007-9022-y
14.	Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage

#### BMJ Open

2		
3		renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis.
5		2002;40(3):611-622. doi:10.1053/ajkd.2002.34924
6 7		
8 9	15.	Akbari A, Clase CM, Acott P, et al. Canadian Society of Nephrology commentary on the
10 11		KDIGO clinical practice guideline for CKD evaluation and management. Am J Kidney
12		
13 14		Dis. 2015;65(2):177-205. doi:10.1053/j.ajkd.2014.10.013
15 16	16.	KDIGO, CKD. KDIGO CPG for evaluation & management of CKD 2013. Kidney Int
17	10.	KDIGO, CKD. KDIGO CFG for evaluation & management of CKD 2015. Kinney Int
18 19		Suppl. 2013;3(1):1-150.
20 21	17	Drimble KC Dell D. Crill AV, at al. Immediated the Kidney Wise to elluit an abronic bidney
22 23	17.	Brimble KS, Boll P, Grill AK, et al. Impact of the KidneyWise toolkit on chronic kidney
24		disease referral practices in Ontario primary care: a prospective evaluation. BMJ Open.
25 26		2020;10(2):e032838. doi:10.1136/bmjopen-2019-032838
27 28		
29	18.	CKD pathway. Accessed June 12, 2021. http://www.ckdpathway.ca/
30 31	10	
32 33	19.	De Coster C, McLaughlin K, Noseworthy TW. Criteria for referring patients with renal
34 35		disease for nephrology consultation: a review of the literature. J Nephrol. 2010;23(4):399-
36		407.
37 38		
39 40	20.	Hommel K, Madsen M, Kamper AL. The importance of early referral for the treatment of
41 42		chronic kidney disease: a Danish nationwide cohort study. <i>BMC Nephrol</i> . 2012;13:108.
43		
44 45		doi:10.1186/1471-2369-13-108
46 47	21.	Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services
48 49		
50		for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev.
51 52		2014;6:CD007333. doi:10.1002/14651858.CD007333.pub2
53 54	22	
55 56	22.	Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system
57		
58 59		17
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

#### **BMJ** Open

characteristics associated with late referral in chronic kidney disease. BMC Nephrol. 2008;9:3. doi:10.1186/1471-2369-9-3 Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk 23. among new ESRD patients in the United States. Am J Kidney Dis. 2003;41(2):301-318. doi:10.1053/ajkd.2003.50038 24. Kazmi WH, Obrador GT, Khan SS, Pereira BJG, Kausz AT. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant. 2004;19(7):1808-1814. doi:10.1093/ndt/gfg573 25. MacKinnon JC. Wait times in Canada. Healthc Manag Forum. 2017;30(4):190-192. doi:10.1177/0840470417700162 Wright J. Glenister KM, Thwaites R, Terry D. The importance of adequate referrals for 26. chronic kidney disease. Aust J Gen Pract. 2018;47(1-2):58-62. doi:10.31128/AFP-08-17-27. Lane C, Pirabhahar S, Robins J, Tranter S, Brown M, Katz I. Improving nephrology service delivery—accessing the specialist. Aust Fam Physician. 2016;45(4):223-228. Bello AK, Ronksley PE, Tangri N, et al. Quality of chronic kidney disease management in 28. Canadian primary care. JAMA Netw open. 2019;2(9):e1910704. doi:10.1001/jamanetworkopen.2019.10704 29. Patwardhan MB, Samsa GP, Matchar DB, Haley WE. Advanced chronic kidney disease practice patterns among nephrologists and non-nephrologists: a database analysis. Clin J Am Soc Nephrol. 2007;2(2):277-283. doi:10.2215/CJN.02600706

30.	Østbye T, Yarnall KSH, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time
	for management of patients with chronic diseases in primary care? Ann Fam Med.
	2005;3(3):209-214. doi:10.1370/afm.310
31.	Yarnall KSH, Pollak KI, Østbye T, Krause KM, Michener JL. Primary care: is there
	enough time for prevention? Am J Public Health. 2003;93(4):635-641.
	doi:10.2105/AJPH.93.4.635
32.	Shojania K, McDonald K, Watcher R, Owens D. Closing the quality gap: a critical
	analysis of quality improvement strategies. Volume 1: series overview and methodology.
	Technical Review 9; 2004.
33.	Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult
	immunization and cancer screening services: A meta-analysis. Ann Intern Med.
	2002;136(9):641-651. doi:10.7326/0003-4819-136-9-200205070-00006
34.	Stafford RS. Alternative strategies for controlling rising cesarean section rates. JAMA.
	1990;263(5):683-687. doi:10.1001/jama.1990.03440050077037
35.	Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease
	management programmes for patients with chronic illnesswhich ones work? Meta-
	analysis of published reports. BMJ. 2002;325:925. doi:10.1136/bmj.325.7370.925
36.	Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of
	systematic reviews of interventions. Med Care. 2001;39(8 Suppl 2):II2-45.
37.	Faulkner A, Mills N, Bainton D, et al. A systematic review of the effect of primary care-
	based service innovations on quality and patterns of referral to specialist secondary care.
	19

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

**BMJ** Open

Br J Gen Pract. 2003;53:878-884.

http://www.ingentaconnect.com/content/rcgp/bjgp/2003/00000053/00000496/art00011%5 Cnhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1314732/pdf/14702909.pdf

- Akbari A, Mayhew A, Al-Alawi MA, et al. Interventions to improve outpatient referrals from primary care to secondary care. *Cochrane Database Syst Rev.* 2008;4:CD005471. doi:10.1002/14651858.CD005471.pub2
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.
   doi:10.1186/2046-4053-4-1
- 40. Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. *J Clin Epidemiol*. 2021;134:103-112. doi:10.1016/j.jclinepi.2021.02.003
- McDonald KM, Chang C, Schultz EJ. Methods research report. Through the quality kaleidoscope: reflections on the science and practice of improving health care quality;
   2013. Accessed June 13, 2021. www.EffectiveHealthCare.ahrq.gov/reports/final.cfm.
- 42. Cochrane Effective Practice and Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews. 2017;1-4.

https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-forauthors2017/suggested\_risk\_of\_bias\_criteria\_for\_epoc\_reviews.pdf


43. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*.
1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2


1		
2 3	44.	Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med.
4 5		
6		2002;21(11):1539-1558. doi:10.1002/sim.1186
7 8		
9	45.	Campbell M, Mckenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in
10 11		systematic reviews: reporting guideline. BMJ. 2020;368:16890. doi:10.1136/bmj.16890
12		
13 14	46.	Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases.
15		
16 17		Health Technol Assess. 2000;4(10). doi:10.3310/hta4100
18		
19 20		
21		
22 23		
24		
25 26		
27		
28 29		
30		
31 32		
33		
34 35		Health Technol Assess. 2000;4(10). doi:10.3310/hta4100
36 37		
38		
39 40		
40		
42 43		
44		
45 46		
47		
48 49		
50		
51 52		
53		
54 55		
56		
57 58		21
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool

Intervention type Provider education Provider reminder systems	Interventions aimed at training care providers, including educational workshops/meetings, outreach programs, and distribution of educational materials
Provider reminder systems	
	Providing specific information about clinical encounters with the a of prompting clinicians to recall information or promote a certain aspect of care
Audit and feedback	Methods that provide a review of clinical performance for health ca providers and institutions to help improve quality of a certain aspec care
Other	<ul> <li>educational materials</li> <li>Providing specific information about clinical encounters with the a of prompting clinicians to recall information or promote a certain aspect of care</li> <li>Methods that provide a review of clinical performance for health caproviders and institutions to help improve quality of a certain aspect care</li> <li>Interventions not covered in the previously listed items, e.g. organizational change initiatives, financial incentives, patient reminsystems, patient education, promotion of self-management, and facilitated relay of clinical data to providers</li> </ul>
	22

	Inclusion criteria	Exclusion criteria
-	Studies involving CKD patients who are not being managed with KRT.	- Studies where referrals are not from PHC to nephrology (e.g. referrals from or to general internal medicine for
-	Studies reporting changes in process- based QI measures (wait times, number	CKD).
	of referrals, or changes in guideline- concordant referrals) for CKD patients.	- Review articles, editorials, letters to the editor, commentaries, case studies, case reports, images.
-	Studies reporting at least one outcome measure (referral numbers, rate or	- Studies where we cannot obtain
	proportion of guideline concordant referrals, or wait times).	relevant data (e.g., method of intervention or outcomes reported) eve after contacting authors.
-	No restrictions on publication date.	C C
-	No restrictions on language.	- Studies where the outcomes of interest (referral numbers, wait times, guideline-concordant referral rate) are
-	No restrictions on the referral guidelines (e.g. KDIGO vs.	not clearly reported.
	local/national guidelines) used.	





BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 32 42 52 66 27 28 29 30 31 32 24 25 26 27 28 29 30 31 32 24 25 26 27 28 29 30 31 32 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 31 41 55 26 27 28 29 30 31 32 34 35 36 37 38 39 40 41 41 55 26 27 28 29 30 31 32 34 35 36 37 38 39 40 41 41 55 26 27 28 29 30 31 32 34 35 36 37 38 39 40 41 41 55 26 27 28 29 30 31 32 34 35 36 37 38 39 40 41 41 55 26 26 27 28 29 30 31 32 34 35 36 37 38 39 40 41 41 55 36 37 38 39 40 41 55 36 37 38 39 40 41 55 55 56 57 56 57 56 57 57 57 57 57 57 57 57 57 57	J
43	
44 45	
46	
47	

	2021			2022
<ul> <li>Jan Feb Mar Apr May Jun</li> <li>Jan 2021 - Jul 2021</li> <li>Protocol development</li> <li>Identification of relevant frameworks</li> <li>Selection of studies</li> <li>Data extraction tool development/relevance for</li> <li>Prospero registration</li> <li>Publication of protocol</li> </ul>	QI •	Sep Oct Nov Dec Jan Aug 2021 - Dec 2021 Identification of relevant publications Data extraction Database development Risk of bias assessment Analysis	Feb Mar Apr May Jun Jan 2022 - Jun 2022 • Manuscript writing/ reporting of results • Publication of original manuscript • Presentation at scientific meetings	<ul> <li>Jul Aug Sep Oct Nov Dec Jac</li> <li>Jul 2022 - Dec 2022</li> <li>KT activities and tools development (lay summaries and policy briefs)</li> <li>Engagement with relevant policy makers, primary care and referral coordinators to effect practice and/or policy change</li> <li>Develop recommendations for guideline developers</li> </ul>

AT-L-ZS2 on 21 April 2023. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool Protected by copyright,אופנווקאסולאראנאנאסיסטפאכאסט Protected by copyright,אופנווקאסולאראלאסטטאיאסטאפאראסטאראסאראסטאראסטאראסטאראסטאנאסאסטאנאסאסטאנאטא און איזאטאטאס

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
22	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
56	
56 57	
57	

60

1

2

## Supplementary Table S1: Medical Subject Headings for MEDLINE database search

	nronic Kidney disease*.mp.
	ronic kidney insufficienc*.mp.
	ronic renal disease*.mp.
5. ch	ronic renal insufficienc*.mp.
6. Cl	KD.mp.
7. Re	enal fail*.mp.
8. Ki	idney fail*.mp.
9. or	/1-8
10. 0	Drganizational innovation/
	linical audit/ or medical audit/ or nursing audit/
	Quality Improvement/
	education/ or education, professional/ or education, continuing/ or education, medical,
	inuing/ or education, nursing, continuing/ or education, professional, retraining/
	Quality* adj2 improv*).mp.
	(Provider or doctor* or physician* or nurse* or health personnel* or healthcare
	onnel*) adj4 (educat* or learn* or "reminder system*")).mp.
	Organization* adj3 (change* or restructure* or revamp or reform* or revise* or
`	vat*)).mp.
	Audit*.mp.
	Feedback/
	eedback.mp.
	Physician Incentive Plans/
	financ* adj2 incentiv*).mp.
	incent* adj2 (plan or plans)).mp.
	ocial control, formal/ or government regulation/ or mandatory programs/ or social contr
	cies/ or organizational policy/ or public policy/ or health policy/ or health care reform/
	egulat*.mp.
	policy or policies).mp.
	poncy of poncies).mp. pr/10-25
	Referral and Consultation"/ or (referral* or consultation* or consults or consult).mp. 26 and 27
	((Improv* or amerlior* or better or enhance* or correct* or increase* or progress or
	itat* or promote* or raise* or augment* or elevate* or appropriate) adj3 (referral* or
	ultation* or consult or consults)) and (guide* or policy or policies or regulation* or
	sit* or report*)).mp.
	(Reduce or reduction* or decrese* or lessen* or minimize* or diminish* or lower* or
,	
	d*) adj3 ((unnecessary or avoidable or superfluous or unneeded or irrelevant or late or tional) adj2 (referrel* or consultation* or consult or consultation)) mp
	tional) adj2 (referral* or consultation* or consult or consults))).mp.
	vait* time*.mp. and ((referral* or consultation* or consult or consults).mp. or "Referral
	Consultation"/) and (guide* or policy or policies or regulation* or toolkit* or
	rting).mp.
	28 or 29 or 30 or 31
33.9	) and 32

1	
2	
3	
4	
5	Appendix: Search strategies for all databases in protocol
6	
7	All searches were conducted with no additional filters or limits.
8 9	
10	Medline – 431 results
11	Ovid MEDLINE(R) ALL
12	
13	1. exp Renal Insufficiency, Chronic/
14	2. Chronic Kidney disease*.mp.
15	3. chronic kidney insufficienc*.mp.
16	4. chronic renal disease*.mp.
17	5. chronic renal insufficienc*.mp.
18	6. CKD.mp.
19 20	7. Renal fail*.mp.
20	8. 12.mp.
21	9. or/1-8
23	10. Organizational innovation/
24	
25	11. clinical audit/ or medical audit/ or nursing audit/
26	12. Quality Improvement/
27	13. education/ or education, professional/ or education, continuing/ or education, medical, continuing/
28	or education, nursing, continuing/ or education, professional, retraining/
29	14. (Quality adj2 improv*).mp.
30	15. ((Provider or doctor* or physician* or nurse* or health personnel* or healthcare personnel*) adj4
31	(educat* or learn* or "reminder system*")).mp.
32	16. (Organization* adj3 (change* or restructure* or revamp* or reform* or revise* or innovat*)).mp.
33	17. Audit*.mp.
34 35	18. Feedback/
36	19. <u>feedback.mp</u> .
37	20. Physician Incentive Plans/
38	21. (financ* adj2 incentiv*).mp.
39	22. (incent* adj2 (plan or plans)).mp.
40	23. social control, formal/ or government regulation/ or mandatory programs/ or social control policies/
41	or organizational policy/ or public policy/ or health policy/ or health care reform/
42	24. regulat*.mp.
43	25. (policy or policies).mp.
44	26. or/10-25
45	27. "Referral and Consultation"/ or (referral* or consultation* or consults or consult).mp.
46	28. 26 and 27
47	29. (((Improv* or amerlior* or better* or enhance* or correct* or increase* or progress* or facilitat* or
48 49	promote* or raise* or augment* or elevate* or appropriate) adj3 (referral* or consultation* or consult
49 50	or consults)) and (guide* or policy or policies or regulation* or toolkit* or report*)).mp.
50	30. ((Reduc* or decrese* or lessen* or minimize* or diminish* or lower* or avoid*) adj3 ((unnecessary
52	
53	or avoidable or superfluous or unneeded or irrelevant or late or traditional) adj2 (referral* or
54	consultation* or consult or consults))).mp.
55	31. wait* time*.mp. and ((referral* or consultation* or consult or consults).mp. or "Referral and
56	Consultation"/) and (guide* or policy or policies or regulation* or toolkit* or reporting).mp.
57	
58	
59	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60	r or peer review only " http://binjopen.binj.com/site/about/guidelines.xittini

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool .

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

2	
3	
4	
3 4 5 6 7 8 9 10	
7	
8	
9	
10	
11	
12	
13	
15	
16	
17	
18	
19	
20	
22	
23	
24	
25	
20 27	
28	
29	
30	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	
32	
34	
35	
36	
37	
38 39	
39 40	
41	
42	
43	
44 45	
45 46	
47	
48	
49	
50	
51 52	
52 53	
54	
55	
56	
57 50	
58 59	
60	

1

15. (Organization\* adj3 (change\* or restructure\* or revamp\* or reform\* or revise\* or innovat\*)).mp. 16. Audit\*.mp. 17. feedback.mp. 18. (financ\* adj2 incentiv\*).mp. 19. (incent\* adj2 (plan or plans)).mp. APA PsycInfo, Ovid platform

11. total quality management/ 12. education/ or adult education/ or continuing education/ or vocational education/

13. (Quality adj2 improv\*).mp.

10. clinical audit/ or nursing audit/

32. 28 or 29 or 30 or 31

Embase – 1322 results

1. exp chronic kidney failure/

2. Chronic Kidney disease\*.mp. 3. chronic kidney insufficienc\*.mp. 4. chronic renal disease\*.mp. 5. chronic renal insufficienc\*.mp.

33.9 and 32

**Ovid platform** 

6. CKD.mp. 7. Renal fail\*.mp. 8. Kidney fail\*.mp.

9. or/1-8

- 14. ((Provider or doctor\* or physician\* or nurse\* or health personnel\* or healthcare personnel\*) adj4 (educat\* or learn\* or "reminder system\*")).mp.

20. social control/ or government regulation/ or mandatory program/ or organizational policy/ or public policy/ or health care policy/

- 21. regulat\*.mp.
- 22. (policy or policies).mp.
- 23. or/10-22

24. exp consultation/ or patient referral/ or (referral\* or consultation\* or consults or consult).mp.

25. 23 and 24

26. (((Improv\* or amerlior\* or better\* or enhance\* or correct\* or increase\* or progress\* or facilitat\* or promote\* or raise\* or augment\* or elevate\* or appropriate) adj3 (referral\* or consultation\* or consult or consults)) and (guide\* or policy or policies or regulation\* or toolkit\* or report\*)).mp.

27. ((Reduce\* or decrese\* or lessen\* or minimize\* or diminish\* or lower\* or avoid\*) adj3 ((unnecessary or avoidable or superfluous or unneeded or irrelevant or late or traditional) adj2 (referral\* or consultation\* or consult or consults))).mp.

28. wait\* time\*.mp. and ((referral\* or consultation\* or consult or consults).mp. or exp consultation/ or patient referral/) and (guide\* or policy or policies or regulation\* or toolkit\* or reporting).mp. 29. 25 or 26 or 27 or 28

30. 9 and 29

PsycINFO – 15 results

1. kidney diseases/

1	
1 2	
3	
4	2. Chronic Kidney disease*.mp.
5	3. chronic kidney insufficienc*.mp.
6	4. chronic renal disease*.mp.
7	5. chronic renal insufficienc*.mp.
8	6. CKD.mp.
9	7. Renal fail*.mp.
10	8. Kidney fail*.mp.
11	9. or/1-8
12	10. clinical audits/
13	11. education/
14	12. (Quality adj2 improv*).mp.
15	
16	13. ((Provider or doctor* or physician* or nurse* or health personnel* or healthcare personnel*) adj4
17	(educat* or learn* or "reminder system*")).mp.
18	14. (Organization* adj3 (change* or restructure* or revamp* or reform* or revise* or innovat*)).mp.
19	15. Audit*.mp.
20	16. feedback.mp.
21	17. (financ* adj2 incentiv*).mp.
22	18. (incent* adj2 (plan or plans)).mp.
23	19. monetary incentives/
24 25	20. policy making/ or government policy making/ or health care policy/ or social control/ or health care
25 26	reform/
20	21. regulat*.mp.
28	22. (policy or policies).mp.
29	23. or/10-22
30	24. professional consultation/ or professional referral/ or (referral* or consultation* or consults or
31	
32	consult).mp.
33	25. 23 and 24
34	26. (((Improv* or amerlior* or better* or enhance* or correct* or increase* or progress* or facilitat* or
35	promote* or raise* or augment* or elevate* or appropriate) adj3 (referral* or consultation* or consult
36	or consults)) and (guide* or policy or policies or regulation* or toolkit* or report*)).mp.
37	27. ((Reduce* or decrese* or lessen* or minimize* or diminish* or lower* or avoid*) adj3 ((unnecessary
38	or avoidable or superfluous or unneeded or irrelevant or late or traditional) adj2 (referral* or
39	consultation* or consult or consults))).mp.
40	28. wait* time*.mp. and ((referral* or consultation* or consult or consults).mp. or professional
41	consultation/ or professional referral/) and (guide* or policy or policies or regulation* or toolkit* or
42	reporting).mp.
43	29. 25 or 26 or 27 or 28
44	30. 9 and 29
45	
46 47	Cochrane – 314 results
47 48	Cochrane Central
40 49	Cochrane Central
50	
51	#1 MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees
52	#2 "Chronic Kidney" NEXT disease*
53	#3 "chronic kidney" NEXT insufficienc*
54	#4 "chronic renal" NEXT disease*
55	#5 "chronic renal" NEXT insufficienc*
56	#6 CKD
57	
58	
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1

2	
3	#7 Renal NEXT fail*
4	#8 Kidney NEXT fail*
5	#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
6	#10 MeSH descriptor: [Organizational Innovation] this term only
7	#11 MeSH descriptor: [Clinical Audit] this term only
8	
9	#12 MeSH descriptor: [Medical Audit] this term only
10	#13 MeSH descriptor: [Nursing Audit] this term only
11	#14 MeSH descriptor: [Quality Improvement] this term only
12	#15 MeSH descriptor: [Education] this term only
13 14	#16 MeSH descriptor: [Education, Professional] in all MeSH products
14	#17 MeSH descriptor: [Education, Continuing] this term only
16	#18 MeSH descriptor: [Education, Medical, Continuing] this term only
17	#19 MeSH descriptor: [Education, Nursing, Continuing] this term only
18	#20 MeSH descriptor: [Education, Professional, Retraining] this term only
19	#21 Quality NEXT improv*
20	#22 (Provider OR doctor* OR physician* OR nurse* OR (health NEXT personnel*) OR (healthcare
21	NEXT personnel*)) NEAR/4 (educat* OR learn* OR (reminder NEXT system*))
22	
23	#23 Organization* NEAR/3 (change* OR restructure* OR revamp* OR reform* OR revise* OR
24	innovat*)
25	#24 audit*
26	#25 MeSH descriptor: [Feedback] this term only
27	#26 Feedback
28	#27 MeSH descriptor: [Physician Incentive Plans] this term only
29	#28 financ* NEAR/2 incentiv*
30	#29 incent* NEAR/2 (plan OR plans)
31	#30 MeSH descriptor: [Social Control, Formal] this term only
32	#31 MeSH descriptor: [Government Regulation] this term only
33	#32 MeSH descriptor: [Mandatory Programs] this term only
34	#33 MeSH descriptor: [Social Control Policies] this term only
35	#34 MeSH descriptor: [Organizational Policy] this term only
36	#35 MeSH descriptor: [Public Policy] this term only
37	
38	#36 MeSH descriptor: [Health Policy] this term only
39	#37 MeSH descriptor: [Health Care Reform] this term only
40	#38 regulat*
41 42	#39 policy OR policies
42 43	#40{OR #10-#39}
43	#41 MeSH descriptor: [Referral and Consultation] this term only
45	#42 referral* OR consultation* OR consults OR consult
46	#43 #41 OR #42
47	#44 #40 AND #43
48	#45 ((Improv* OR amerlior* OR better* OR enhance* OR correct* OR increase* OR progress* OR
49	facilitat* OR promote* OR raise* OR augment* OR elevate* OR appropriate) NEAR/3 (referral*
50	OR consultation* OR consult OR consults)) AND (guide* OR policy OR policies OR regulation* OR
51	
52	toolkit* OR report*)
53	#46 ((Reduc* OR decrese* OR lessen* OR minimize* OR diminish* OR lower* OR avoid*) NEAR/3
54	((unnecessary OR avoidable OR superfluous OR unneeded OR irrelevant OR late OR traditional)
55	NEAR/2 (referral* OR consultation* OR consult OR consults)))
56	
57	
58	
59	

1	
2	
3	#47 (wait* NEXT time*) AND (#43 AND (guide* OR policy OR policies OR regulation* OR toolkit* OR
4	reporting))
5	#48 {OR #44-#47}
6	#49 #9 AND #48
7	
8 9	314 results
10	
11	
12	CINAHL – 251 results
13	
14	CINAHL Plus with Full Text, EBSCO platform
15	
16	S1 (MH "Kidney Failure, Chronic")
17	S2 "Chronic Kidney disease*"
18	S3 "chronic kidney insufficienc*"
19	S4 "chronic renal disease*"
20	S5 "chronic renal insufficienc*"
21	S6 CKD
22	S7 "Renal fail*"
23 24	S8 "Kidney fail*"
24 25	S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
26	S10 (MH "Nursing Audit") OR (MH "Audit")
27	S11 (MH "Quality Improvement")
28	S12 (MH "Education")
29	S13 (MH "Refresher Courses")
30	S14 (MH "Education, Continuing+") OR (MH "Education, Medical, Continuing") OR (MH "Education,
31	Nursing, Continuing") OR (MH "Education, Continuing (Credit)")
32	S15 Quality N2 improv*
33	S16 (Provider OR doctor* OR physician* OR nurse* OR "health personnel*" OR "healthcare
34	personnel*") N4 (educat* OR learn* OR "reminder system*")
35	S17 Organization* N3 (change* OR restructure* OR revamp* OR reform* OR revise* OR innovat*)
36	S17 Organization NS (change OK restructure OK revamp OK reform OK revise OK innovat )
37	
38 39	S19 (MH "Feedback")
39 40	S20 Feedback
40 41	S21 (MH "Physician Incentive Plans")
42	S22 financ* N2 incentiv*
43	S23 incent* N2 (plan OR plans))
44	S24 (MH "Social Control") OR (MH "Public Policy") OR (MH "Health Policy")
45	S25 (MH "Government Regulations")
46	S26 (MH "Organizational Policies") OR (MH "Hospital Policies")
47	S27 (MH "Health Care Reform")
48	S28 regulat*
49	S29 (policy OR policies)
50	S30 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
51 52	OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29
52 53	S31 (MH "Referral and Consultation")
53 54	S32 referral* OR consultation* OR consults OR consult
55	S33 S31 OR S32
56	S34 S30 AND S33
57	
58	
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- S35 (((Improv\* OR amerlior\* OR better\* OR enhance\* OR correct\* OR increase\* OR progress\* OR 6facilitate\* OR promote\* OR raise\* OR augment\* OR elevate\* OR appropriate) N3 (referral\* OR consultation\* OR consult OR consults)) AND (guide\* OR policy OR policies OR regulation\* OR toolkit\* OR report\*))
- S36 ((Reduc\* OR decrese\* OR lessen\* OR minimize\* OR diminish\* OR lower\* OR avoid\*) N3 ((unnecessary OR avoidable OR superfluous OR unneeded OR irrelevant OR late OR traditional) N2 (referral\* OR consultation\* OR consult OR consults)))
- S37 "wait\* time\*" AND (S33 AND (guide\* OR policy OR policies OR regulation\* OR toolkit\* OR reporting))

S38 S34 OR S35 OR S36 OR S37

S39 S9 AND S38

WoS – 589 results Web of Science – All databases

- TS=("Chronic Kidney disease\*" OR "chronic kidney insufficienc\*" OR "chronic renal disease\*" OR "chronic renal insufficienc\*" OR "CKD" OR "Renal fail\*" OR "Kidney fail\*")
- 2. TS=(((((Quality NEAR/2 improv\*) OR ((Provider OR doctor\* OR physician\* OR nurse\* OR "health personnel\*" OR "healthcare personnel\*") NEAR/4 (educat\* OR learn\* OR "reminder system\*")) OR (Organization\* NEAR/3 (change\* OR restructure\* OR revamp\* OR reform\* OR revise\* OR innovat\*)) OR Audit\* OR Feedback OR (financ\* NEAR/2 incentiv\*) OR (incent\* NEAR/2 (plan OR plans)) OR regulat\* OR policy OR policies) AND (referral\* OR consultation\* OR consults OR consult)) ))
- **3.** TS=(("wait\* time\*" AND (referral\* OR consultation\* OR consults OR consult) AND (guide\* OR policy OR policies OR regulation\* OR toolkit\* OR reporting)))
- 4. TS=((((Improv\* OR amerlior\* OR better\* OR enhance\* OR correct\* OR increase\* OR progress\* OR facilitat\* OR promote\* OR raise\* OR augment\* OR elevate\* OR appropriate) NEAR/3 (referral\* OR consultation\* OR consult OR consults)) AND (guide\* OR policy OR policies OR regulation\* OR toolkit\* OR report\*)))
- 5. TS=(((Reduc\* OR decrese\* OR lessen\* OR minimize\* OR diminish\* OR lower\* OR avoid\*) NEAR/3 ((unnecessary OR avoidable OR superfluous OR unneeded OR irrelevant OR late OR traditional) NEAR/2 (referral\* OR consultation\* OR consult OR consults))))
- 6. #2 OR #3 OR #4 OR #5
- **7.** #1 AND #6

# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 Syst Rev. 2015;4(1):1.			statement.
			Page
		Reporting Item	Number
Title			
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	1
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic	N/A
		review, identify as such	
	For nee	r review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml	

1 2 3	Registration			
4 5		<u>#2</u>	If registered, provide the name of the registry (such as	2
6 7			PROSPERO) and registration number	
8 9 10 11	Authors			
12 13 14	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all	otected by 1
14 15 16			protocol authors; provide physical mailing address of	у соруп
17 18			corresponding author	vigni,
19 20				
21 22	Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the	14
23 24			guarantor of the review	
25 26	Amendments			
27 28				
29 30		<u>#4</u>	If the protocol represents an amendment of a previously	N/A
31 32			completed or published protocol, identify as such and list	
33 34			changes; otherwise, state plan for documenting important	
35 36			protocol amendments	, inde
37 38			0,	
39 40	Support			,
41 42 43 44	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	14 sminu
44 45 46 47	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	14
48 49	Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or	14 14
50 51	funder		institution(s), if any, in developing the protocol	
52 53 54 55 56 57	Introduction			
58 59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is	3-8	BMJ Open: first published as 10.1136/bmjopen-2021-055456 on
4 5 6 7 8			already known		ben: f
	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review	8	irst put
8 9 10			will address with reference to participants, interventions,	σ	olished
11 12			comparators, and outcomes (PICO)	Protected by copyright, including for uses 23 9, 8-9	l as 10.
13 14 15	Methods			ed by o	.1136/k
16				юруг	omjop
17 18	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study	8-9, 23 <mark>igh</mark> t, ir	oen-20;
19 20 21			design, setting, time frame) and report characteristics (such	ncludir	21-055
22 23			as years considered, language, publication status) to be	ng for t	456 or
24 25			used as criteria for eligibility for the review		1 21 Ap
26 27	Information	#9	Describe all intended information sources (such as	related 8-9	21 April 2022 Erasmu
28 29 30	sources		electronic databases, contact with study authors, trial	to text	2. Dov
31 32 33 34			registers or other grey literature sources) with planned dates	and di	vnload Iescho
			of coverage	ata mir	ed froi ol .
35 36				ning,	from http:/
37 38	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one	9-10, 25 Al trai	
39 40			electronic database, including planned limits, such that it	ning, a	jopen.
41 42 43			could be repeated	ind sim	bmj.co
44 45 46 47 48 49 50	Study records -	<u>#11a</u>	Describe the mechanism(s) that will be used to manage	9-10, 25 10 10	bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA
	data management		records and data throughout the review	hnolog	lay 5, 2
				•	2025 a
51	Study records -	<u>#11b</u>	State the process that will be used for selecting studies	10	t Dep
52 53 54 55 56 57 58	selection process		(such as two independent reviewers) through each phase of		artme
			the review (that is, screening, eligibility and inclusion in		nt GE
			meta-analysis)		Z-LTA
59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

BMJ Open: first published as 10.1136/bmjopen-2021-055456 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on May 5, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2	Study records -	<u>#11c</u>	Describe planned method of extracting data from reports	10
3 4	data collection		(such as piloting forms, done independently, in duplicate),	
5 6 7	process		any processes for obtaining and confirming data from	
7 8 9			investigators	
10 11 12	Data items	<u>#12</u>	List and define all variables for which data will be sought	9
13 14			(such as PICO items, funding sources), any pre-planned	
15 16 17			data assumptions and simplifications	
18 19	Outcomes and	<u>#13</u>	List and define all outcomes for which data will be sought,	10
20 21 22	prioritization		including prioritization of main and additional outcomes, with	
23 24 25			rationale	
26 27	Risk of bias in	<u>#14</u>	Describe anticipated methods for assessing risk of bias of	11
28 29 20	individual studies		individual studies, including whether this will be done at the	
30 31 32			outcome or study level, or both; state how this information	
33 34 35			will be used in data synthesis	
36 37	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be	11
38 39 40			quantitatively synthesised	
41 42 42	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe	11
43 44 45			planned summary measures, methods of handling data and	
46 47			methods of combining data from studies, including any	
48 49 50			planned exploration of consistency (such as I2, Kendall's $\tau$ )	
51 52	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as	11
53 54 55			sensitivity or subgroup analyses, meta-regression)	
56 57 58				
59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1				N.L./ A
2	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the type	N/A
3 4			of summary planned	
5 6				
7	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as	11
8 9			publication bias across studies, selective reporting within	
10 11				-
12			studies)	
13 14	Confidence in	#17	Describe how the strength of the body of evidence will be	N/A 3
15 16		<u>#11</u>		
17	cumulative		assessed (such as GRADE)	9
18 19	evidence			, ,
20 21				2
22	The PRISMA-P elal	ooration	and explanation paper is distributed under the terms of the Creative	e c
23 24	Commons Attributic	n Licens	se CC-BY. This checklist was completed on 28. June 2021 using	200
25 26				
27 28	https://www.goodre	ports.org	<u>/</u> , a tool made by the <u>EQUATOR Network</u> in collaboration with	
29	Penelope.ai			ġ
30 31				2
32 33				2
34				2
35 36				ų
37 38				1
39				2
40 41				ų
42 43				2
44				2
45 46				
47 48				
49				
50 51				
52 53				
54				
55 56				
57 58				
59		Ferrer	review only - http://bmionen.bmi.com/site/about/quidelines.xhtml	
60		FULDEAL	review only - http://philopen.phil.com/sile/about/guidelines.xntml	